Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × Thyroxine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 7 Hypothyroidism 5 Thyroid Diseases 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Postoperative Complications 1 Polycystic Ovary Syndrome 1 Neoplasms 1 Infertility, Female 1 Goiter 1 Fatigue 1 Depression 1 Anxiety Disorders 1 Advanced Differentiated Thyroid Gland Carcinoma 1

Interventions

pembrolizumab 155 Gemcitabine 146 Paclitaxel 134 Carboplatin 120 Bevacizumab 116 Docetaxel 100 Cyclophosphamide 100 Cisplatin 99 Exercise 82 Nivolumab 81 Capecitabine 80 Fluorouracil 78 Dexamethasone 74 Irinotecan 68 Oxaliplatin 62 Pemetrexed 60 Radiotherapy 59 Leucovorin 57 Standard of Care 56 Cetuximab 50 Blood Specimen Collection 48 Sorafenib 47 Drug Therapy 47 Erlotinib Hydrochloride 46 Doxorubicin 44 atezolizumab 41 130-nm albumin-bound paclitaxel 39 trametinib 37 Ipilimumab 36 Albumin-Bound Paclitaxel 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡